Cencora
Cencora moves prescription drugs from manufacturers to pharmacies and hospitals across the US.
The call
Cencora sits inside a three-company system that moves nearly all US prescription drugs, a position built on licenses and infrastructure that neither AI nor a single rival can quickly copy.
Cencora is one of three companies that move almost all prescription medicines from drug makers to pharmacies and hospitals across America, handling $321 billion in goods per year. It is extremely hard to copy or replace because the government tightly controls who can distribute controlled drugs like opioids, and Cencora has built 25+ refrigerated warehouses and locked-in deals with thousands of pharmacies and hospitals that would take years and billions to replicate; neither AI nor a rival can easily recreate that overnight. The thing to watch is whether lawsuits over opioid sales force Cencora to pay out so much money that it weakens the business, and whether its newer specialty-care business (OneOncology) can grow fast enough to justify the debt taken on to build it.
Why
01
AI pressure: None apparent. AI tools help Cencora forecast demand and route shipments internally; no AI product replaces DEA-licensed drug distribution itself. Could AI do the core job? Unlikely.
02
Bigger players: CVS Health, UnitedHealth/Optum, Amazon Pharmacy. These payers could try building their own wholesale drug pipelines to cut out Cencora, but none has shipped real volume yet. Could a giant copy it? No, they are blocked.
03
What protects it. DEA controlled-substance licenses, cold-chain warehouses, and decades-old contracts with manufacturers and pharmacies that can't be replicated quickly.
What would change this call
CVS Health, UnitedHealth/Optum, or Amazon ships national wholesale distribution with signed volume commitments. Would show vertical integration finally displacing Cencora's distribution role.
Q3 FY2026 earnings on August 5, 2026 show another revenue miss or guidance cut. Would show operational strain beyond the prior quarter's stock drop.
Ruling or settlement outcome in the revived $2.5B West Virginia opioid suit. Would show whether litigation risk exceeds already-priced settlement assumptions.
Q3 FY2026 earnings on August 5, 2026 show another revenue miss or guidance cut. Would show operational strain beyond the prior quarter's stock drop.
Ruling or settlement outcome in the revived $2.5B West Virginia opioid suit. Would show whether litigation risk exceeds already-priced settlement assumptions.
Key numbers
- FY2025 revenue: $321.3 billion
- Paid ~$3.6B for majority OneOncology stake
- Market cap around $62.0 billion
Named risks
- Revived $2.5 billion West Virginia opioid suit and new 2026 school-board suit.
- OneOncology debt integration adding ~$480-500M annual interest expense.
- Customer losses and manufacturer price cuts drove Q2 FY2026 revenue miss.
- GLP-1 drug demand growth slower than anticipated, pressuring a growth driver.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| McKesson Corporation | contesting | With Cencora and Cardinal Health controls over 90% of US drug distribution, per Morningstar, 2026-05-05 |
| Cardinal Health | gaining on | Building competing specialty MSO platforms like Solaris Health while supplying ~25% of US market, 2026-07-08 |
| CVS Health | contesting | Vertically-integrated payer seen as potential wholesale disintermediation threat, no shipped volume as of July 2026 |
| UnitedHealth/Optum | contesting | Named as adjacent vertically-integrated competitor, no announced parallel distribution operation as of July 2026 |
Questions people ask
- Is Cencora in financial trouble?
- No signs of financial trouble show up in the numbers: Cencora posted FY2025 revenue of $321.3 billion, up 9.3% year over year for the year ended September 30, 2025. Q2 FY2026 revenue was $78.36 billion with adjusted diluted EPS of $4.75, slightly below the $4.82 consensus, for the quarter ended March 31, 2026.
- Who are Cencora's biggest competitors?
- Cencora's main competitors are McKesson and Cardinal Health, the other two members of the closed three-firm US drug distribution oligopoly. Share moves between these three incumbents rather than from outside entrants, as shown when McKesson won the OptumRx distribution contract away from Cardinal Health in 2025.
- Is Cencora at risk from AI?
- AI disruption is rated not applicable for Cencora, since no AI product can move physical drugs through cold chain or hold a DEA license. Its shield is DEA and FDA licensure plus decades-long manufacturer contracts, protections that sit outside anything an AI-driven model could replicate.
- What is Cencora's biggest risk?
- The bigger threat is not outside disruption but contract-switching within the existing oligopoly, as seen when McKesson took the OptumRx distribution contract from Cardinal Health in 2025. Cencora also faces margin pressure from IRA list-price cuts costing about $2 billion per quarter as of May 6, 2026, a policy headwind rather than a competitive one.
- Could a big tech or healthcare giant disrupt Cencora's business?
- This threat looks distant. Payers like Optum, CVS, and UnitedHealth own PBMs and could in theory route around distributors, but as of July 2026 none have built the licensure and cold-chain network needed to replace Cencora's scale.
- What should I watch to see how Cencora is doing?
- Two dated items are worth checking: whether Cencora's FY2026 adjusted diluted EPS lands within its guided $17.70 to $17.90 range by the end of calendar 2026, and whether any PBM or manufacturer coalition builds a direct-to-pharmacy distribution model that visibly pulls volume from the Big Three by the end of 2027. Cencora's Q3 FY2026 earnings release, alongside CFO James Cleary's planned retirement transition, is the next near-term checkpoint in mid-2026.
Timeline
- 2026-07-01Cencora announces Eva Boratto as EVP/CFO effective June 29, 2026, succeeding retiring James Cleary
- 2026-06-17Launches next-generation Nucleus inventory solution with multi-site specialty pilot
- 2026-05-06Q2 FY2026 revenue of $78.36B misses consensus, stock falls about 16.7% in one day
- 2026-02-13Closes $3 billion senior notes offering to repay OneOncology acquisition debt
- 2026-02-05Closes majority OneOncology acquisition for approximately $3.6 billion
- 2026-02-05New West Virginia school-board opioid suit filed against Cencora
- 2026-01-12Closes $5.5 billion of credit facilities for OneOncology acquisition
- 2025-10-294th Circuit revives $2.5 billion West Virginia opioid public-nuisance suit
- 2025-01-02Closes acquisition of approximately 85% of Retina Consultants of America for ~$4.4B
- 2023-08-30AmerisourceBergen Corporation rebrands as Cencora
Head to head
Revision history
30 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Cencora
- Cencora Org Chart (2026-03-31)
- GRUFocus (2026-07-30)
- Cencora (COR) Expected to Release Earnings on Wednesday (2026-07-29)
- As Cencora Closes With OneOncology, Patton Says Terms Show "Trust" (2026-02-06)
- Cencora Inc's $5.5 Billion of Credit Facilities
- Cencora Inc's $3 Billion Registered Senior Notes Offering
- Cencora Reports Fiscal 2026 First Quarter Results (2026-02-04)
- Cencora Q2 FY2026 Slides Strategic Moves Amid Revenue Miss (2026-05-06)
- Cencora (COR) Q2 2026 Earnings Transcript (2026-05-06)
- Morningstar Cencora Report (2026-05-05)
- Cencora Employees